HALOZYME THERAPEUTICS, INC.HALOEarnings & Financial Report
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
Revenue
$354.3M
Gross Profit
$299.0M
Operating Profit
$217.9M
Net Profit
$175.2M
Gross Margin
84.4%
Operating Margin
61.5%
Net Margin
49.5%
YoY Growth
22.1%
EPS
$1.43
Financial Flow
HALOZYME THERAPEUTICS, INC. Q3 2025 Financial Summary
HALOZYME THERAPEUTICS, INC. reported revenue of $354.3M (up 22.1% YoY) for Q3 2025, with a net profit of $175.2M (up 27.9% YoY) (49.5% margin). Cost of goods sold was $55.2M, operating expenses totaled $81.1M.
Key Financial Metrics
| Total Revenue | $354.3M |
|---|---|
| Net Profit | $175.2M |
| Gross Margin | 84.4% |
| Operating Margin | 61.5% |
| Report Period | Q3 2025 |
Revenue Breakdown
HALOZYME THERAPEUTICS, INC. Q3 2025 revenue of $354.3M breaks down across 6 segments, led by Royalty at $236.0M (66.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Royalty | $236.0M | 66.6% |
| Proprietary Products Sales | $52.2M | 14.7% |
| Bulkr Hu PH20 | $32.5M | 9.2% |
| Sales Based Milestone | $20.0M | 5.6% |
| Device Partnered Products | $9.5M | 2.7% |
| Device Licensing And Development | $4.0M | 1.1% |
HALOZYME THERAPEUTICS, INC. Revenue by Segment — Quarterly Trend
HALOZYME THERAPEUTICS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Royalty and Proprietary Products Sales) has evolved quarter over quarter.
| Segment | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Royalty | $258.0M | $236.0M | $205.6M | $168.2M |
| Proprietary Products Sales | $59.6M | $52.2M | $46.5M | $36.3M |
| Bulkr Hu PH20 | — | $32.5M | $23.3M | $27.0M |
| Sales Based Milestone | — | $20.0M | $10.0M | — |
| Device Partnered Products | $12.9M | $9.5M | $11.8M | $14.7M |
HALOZYME THERAPEUTICS, INC. Annual Revenue by Year
HALOZYME THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.4B).
| Year | Annual Revenue |
|---|---|
| 2025 | $1.4B |
| 2024 | $1.0B |
| 2023 | $829.3M |
| 2022 | $660.1M |
HALOZYME THERAPEUTICS, INC. Quarterly Revenue & Net Profit History
HALOZYME THERAPEUTICS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 2025 | $451.8M | +51.6% | $-141.6M | -31.3% |
| Q3 2025 | $354.3M | +22.1% | $175.2M | 49.5% |
| Q2 2025 | $325.7M | +40.8% | $165.2M | 50.7% |
| Q1 2025 | $264.9M | +35.2% | $118.1M | 44.6% |
| Q4 2024 | $298.0M | +29.5% | $137.0M | 46.0% |
| Q3 2024 | $290.1M | +34.3% | $137.0M | 47.2% |
| Q2 2024 | $231.4M | +4.7% | $93.2M | 40.3% |
| Q1 2024 | $195.9M | +20.8% | $76.8M | 39.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $195.9M | $231.4M | $290.1M | $298.0M | $264.9M | $325.7M | $354.3M | $451.8M |
| YoY Growth | 20.8% | 4.7% | 34.3% | 29.5% | 35.2% | 40.8% | 22.1% | 51.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.84B | $1.97B | $2.12B | $2.06B | $2.20B | $2.05B | $2.22B | $2.53B |
| Liabilities | $1.66B | $1.68B | $1.67B | $1.70B | $1.71B | $1.72B | $1.72B | $2.48B |
| Equity | $177.8M | $289.4M | $452.7M | $363.8M | $482.3M | $332.7M | $503.9M | $48.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $129.4M | $55.8M | $115.4M | $178.5M | $154.2M | $99.7M | $178.6M | $219.0M |